- Conditions
- Soft Tissue Defects, Soft Tissue Wounds, Traumatic Soft Tissue Defect
- Interventions
- Myriad™ applied in conjunction with NPWT, NPWT Alone
- Device
- Lead sponsor
- Aroa Biosurgery Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • San Antonio, Texas
Location Directory
Clinical trials in San Antonio, Texas
This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
3166
Shown on this page
12
Current sort
Recently updated
Location scope
San Antonio, TX
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1069–1080 of 3,166 matching trials in San Antonio, TX.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
- Interventions
- Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Pheonix, Arizona + 79 more
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Low Grade Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Hodgkin Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Hodgkin Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor
- Interventions
- Tazemetostat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
- Conditions
- Multiple Myeloma
- Interventions
- First-line therapy, Second-line Multiple Myeloma treatments
- Other · Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,011 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 252
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 211 more
- Conditions
- Ulcerative Colitis
- Interventions
- emvistegrast, Placebo-to-match emvistegrast
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 57
- States / cities
- Peoria, Arizona • Camarillo, California • Garden Grove, California + 46 more
- Conditions
- Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
- Interventions
- GM-CSF, Placebo
- Drug · Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Oakland, California + 21 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 21
- States / cities
- Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 12 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- NNC0480-0389, Semaglutide, Placebo (NNC080-0389), Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 71
- States / cities
- Anniston, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
- Conditions
- Solid Tumor
- Interventions
- BNT142
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania + 3 more
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Interventions
- SYS6043
- Drug
- Lead sponsor
- Conjupro Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- rAAV2tYF-GRK1-hRPGRco, Control
- Biological · Drug
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 12 Years to 50 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 15 more
- Conditions
- Obesity
- Interventions
- Fit for Duty-mobile, m-Health Control
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas